DEF: Aptevo Therapeutics Seeks Shareholder Approval for Reverse Stock Split, Equity Raises, and Executive Compensation Amid Nasdaq Listing Concerns

Aptevo Therapeutics Inc. is seeking stockholder approval for a series of critical proposals at its upcoming 2025 Annual Meeting, including a reverse stock split to maintain Nasdaq listing, significant equity issuances for capital, and a new stock incentive plan, all aimed at bolstering its financial position and operational flexibility.

Summary

• Aptevo Therapeutics Inc. will hold its 2025 Annual Meeting of Stockholders virtually on July 24, 2025, at 10 a.m. Pacific Time, with a record date of June 20, 2025, and 3,224,156 shares of common stock outstanding.
• Stockholders will vote on eight key proposals, including the election of two director nominees, ratification of Baker Tilly US, LLP as the independent auditor for 2025 (with audit fees of $453,521 in 2024 and $365,000 in 2023).
• A reverse stock split proposal seeks approval for a ratio between 1-for-6 and 1-for-22, at the Board's discretion, to maintain Nasdaq listing compliance, following previous splits of 1-for-37 (December 3, 2024), 1-for-20 (May 23, 2025), and 1-for-44 (March 5, 2024), which cumulatively exceed a 250-to-1 ratio, potentially precluding future cure periods.
• Approval is sought for the potential issuance of 19.99% or more of outstanding common stock under a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the company to sell up to $25.0 million in common stock at 96% of the lowest daily VWAP.
• A new Third Amended and Restated 2018 Stock Incentive Plan proposes authorizing an additional 250,000 shares, valued at approximately $1,042,500 as of June 20, 2025, to ensure sufficient equity awards for employee retention and motivation, as only 160 shares remained available under the current plan.
• The company's overhang, including the proposed new shares, would be 1.61%, with a three-year average Value-Adjusted Burn Rate of 11.59% (0.00% in 2024, 23.77% in 2023, 11.00% in 2022).
• A non-binding advisory vote on 2024 executive compensation is included, with CEO Marvin L. White's total compensation at $906,020, EVP & COO Jeffrey G. Lamothe at $708,264, and SVP, General Counsel SoYoung Kwon at $641,672; 2024 target bonuses were paid out at 72% for corporate goals and 100% for individual performance.
• Stockholders will also vote on the issuance of more than 19.99% of outstanding common stock, including 12,325,000 shares issuable upon exercise of common warrants from a registered direct offering on June 20, 2025, which generated net proceeds of approximately $7.2 million.
• The company reported a net loss of $(24,130,000) in 2024, compared to $(17,411,000) in 2023 and a net income of $8,027,000 in 2022.
• The Board recommends voting 'FOR' all proposals, including an authorization to adjourn the meeting if necessary to solicit additional proxies.

Sentiment

Score: 4

Explanation: The document outlines critical proposals to address significant challenges, particularly Nasdaq listing compliance and capital needs. While the proposals aim to stabilize and fund the company, the underlying necessity for such measures (e.g., repeated reverse splits, substantial dilution) indicates a precarious financial position for a pre-commercial entity. The sentiment is cautious, reflecting efforts to mitigate risks rather than reporting strong operational success.

Positives

• The company is actively addressing its Nasdaq listing compliance by proposing a reverse stock split.
• Secured approximately $7.2 million in net proceeds from a recent registered direct offering, providing capital for operations and clinical development.
• The Standby Equity Purchase Agreement (SEPA) with Yorkville provides a flexible and reliable source of up to $25.0 million in capital for working capital and general corporate purposes.
• The proposed Third Amended and Restated 2018 Stock Incentive Plan aims to ensure continued ability to attract, retain, and motivate key personnel through equity-based incentives.
• The Board of Directors maintains strong corporate governance practices, with 83% board independence and 100% independence for key committees (Audit, Compensation, Nominating and Corporate Governance).
• The company has a clear policy prohibiting directors, officers, and employees from hedging company equity securities, aligning interests with stockholders.
• A clawback policy for incentive-based compensation in the event of material financial restatements has been adopted, enhancing accountability.
• The company emphasizes a positive employee relationship, offering competitive compensation, comprehensive benefits, and an unlimited paid time off policy.

Negatives

• The company faces ongoing challenges with its Nasdaq listing, requiring repeated reverse stock splits, which can be viewed negatively by investors.
• The cumulative effect of prior reverse stock splits (1-for-44 in March 2024, 1-for-37 in December 2024, 1-for-20 in May 2025) exceeding a 250-to-1 ratio means the company will not be eligible for a compliance period if it fails the Nasdaq bid price requirement again within two years of March 5, 2024.
• The proposed equity issuances, particularly the 12,325,000 shares from common warrants and potential SEPA shares, will result in significant dilution for current stockholders.
• The company reported increased net losses in 2024 ($(24,130,000)) and 2023 ($(17,411,000)), indicating continued financial challenges as a pre-commercial entity.
• Executive and non-employee director stock ownership guidelines are currently not met due to declining stock price, suggesting a disconnect between compensation and stock performance.
• The 2024 Value-Adjusted Burn Rate for equity awards was 0.00%, which, while seemingly low, is due to no equity awards being granted in 2024 as per the VABR table, despite the Summary Compensation Table showing equity awards for NEOs in 2024, indicating potential inconsistencies or specific calculation methods that might obscure actual equity usage.

Risks

• Failure to maintain Nasdaq listing due to not meeting the $1.00 bid price requirement, which would adversely affect liquidity and market price of common stock.
• Potential negative investor perception and further stock price decline following a reverse stock split, as historical outcomes for similar actions are varied.
• Increased transaction costs for stockholders holding 'odd lots' (fewer than 100 shares) after a reverse stock split.
• Significant dilution of existing stockholders' ownership percentage and voting power due to the issuance of shares under the SEPA and upon exercise of common warrants.
• Difficulty in finding alternative sources of capital on favorable terms if stockholders do not approve the SEPA Share Issuance Proposal or the Stock Issuance and Warrant Proposal.
• The company's reliance on equity compensation for attracting and retaining talent may be impaired if the Stock Incentive Plan Proposal is not approved, potentially forcing an increase in cash compensation and reducing resources for business needs.
• The market price of common stock may decrease due to factors unrelated to the reverse stock split, even if implemented.
• Provisions within the Common Warrants could discourage a third-party acquisition of the company, potentially limiting opportunities for stockholders to dispose of shares at a higher price.

Future Outlook

The company intends to use the net proceeds from its recent offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes. The proposed SEPA provides a reliable source of capital for these ongoing needs and the selective pursuit of business development opportunities, including product or technology investment. The increased share reserve under the new stock incentive plan is expected to meet grant needs until approximately December 31, 2026, assuming relative stock price stability.

Management Comments

• The Board believes that the proposed Reverse Stock Split is a potentially effective means for us to continue to maintain compliance with the Bid Price Requirement and to avoid, or at least mitigate, the likely adverse consequences of our Common Stock being delisted from The Nasdaq Capital Market.
• The Board has determined that the SEPA and our ability to issue the Common Stock thereunder in excess of the SEPA Exchange Cap are in the best interests of the Company and its shareholders because the ability to sell Common Stock to Yorkville provides us with a reliable source of capital for general corporate purposes.
• The Board believes that it is in the best interests of the Company and its stockholders to approve the Third Amended and Restated 2018 Stock Incentive Plan in order to continue to motivate outstanding performance by our executive officers, employees, consultants, advisors, and non-employee directors.
• The Board and the Compensation Committee value the opinions of our stockholders and will review and consider the voting results when making future compensation decisions for our named executive officers.

Industry Context

Aptevo Therapeutics operates within the biotechnology and pharmaceutical industry, characterized by high capital requirements for product development and clinical trials. The company's repeated need for reverse stock splits and significant equity raises highlights the challenges faced by pre-commercial biotech firms in maintaining public listing requirements and securing funding. The reliance on equity-based compensation and the focus on human capital management reflect common industry practices for attracting and retaining specialized talent in a competitive environment.

Comparison to Industry Standards

• The company's efforts to maintain its Nasdaq listing, including multiple reverse stock splits, are a direct response to Nasdaq Marketplace Rules, particularly the $1.00 bid price requirement, which is a standard for national securities exchanges.
• The cumulative reverse stock split ratio of 250 shares or more to one, as effectuated by the March 2024, December 2024, and May 2025 splits, places the company in a specific category under Nasdaq Listing Rule 5810(c)(3)(A)(iv), meaning it will not be eligible for a compliance period if it fails the bid price requirement again within two years of March 5, 2024, a more stringent condition compared to companies with less frequent splits.
• The proposed SEPA and warrant issuance, requiring stockholder approval for issuances exceeding 19.99% of outstanding common stock at a discount, aligns with Nasdaq Listing Rules 5635(d) and 5635(b), which are standard governance requirements for equity financings.
• The Compensation Committee's engagement of Willis Towers Watson as an independent compensation consultant and its review of competitive market data for executive and director compensation indicate adherence to common industry practices for compensation benchmarking, although specific comparable companies are not named.
• The adoption of a clawback policy for incentive-based compensation, regardless of fault, is in line with recent SEC and Nasdaq rules stemming from the Dodd-Frank Act, demonstrating compliance with evolving corporate governance standards.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will experience significant dilution from the issuance of shares under the SEPA and upon exercise of the common warrants. Their percentage ownership and voting power will decrease. The reverse stock split aims to maintain Nasdaq listing, which could benefit liquidity and investor interest, but also carries risks of negative perception and potential delisting without a cure period.
• **Employees**: The proposed Stock Incentive Plan is crucial for attracting, retaining, and motivating employees through equity awards. Failure to approve it could lead to increased cash compensation, potentially impacting other business needs. The company maintains a hybrid working environment and focuses on employee safety and well-being.
• **Customers/Industry Partners**: Maintaining Nasdaq listing is important for the company's visibility and credibility, which can influence potential industry partners and collaborators. Delisting could cause a loss of confidence and harm business prospects.
• **Creditors/Lenders**: The ability to raise capital through equity issuances (SEPA, warrants) directly impacts the company's financial health and ability to meet obligations, which is critical for creditors and lenders. Failure to secure this capital could impair working capital and lead to less advantageous financing options.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on July 24, 2025, to vote on the proposed resolutions.
• If approved, the Board will determine the specific ratio and timing for the reverse stock split, to be effected on or prior to December 31, 2025.
• If the Stock Issuance and Warrant Proposal is not approved at the Annual Meeting, the company will be required to call a meeting every sixty days thereafter to seek stockholder approval until it is obtained or the Common Warrants are no longer outstanding.
• If the Third Amended and Restated 2018 Stock Incentive Plan is approved, it will become effective on July 24, 2025, and the company intends to file a registration statement on Form S-8 covering the new shares.
• The Audit Committee will continue its primary oversight over the company's ESG activities, coordinating with the Compensation and Nominating and Corporate Governance Committees.
• Management will continue to monitor and focus on human capital resources, including recruiting, retention, and employee well-being.

Key Dates

Keywords

SEC filing, Proxy Statement, Annual Meeting, Reverse Stock Split, Nasdaq Listing, Equity Issuance, Capital Raise, Standby Equity Purchase Agreement, SEPA, Stock Incentive Plan, Executive Compensation, Corporate Governance, Dilution, Biotechnology, Clinical Development, Warrants, Shareholder Approval, Risk Management, Financial Reporting